Finance

Beta
Lists
GPCR:NASDAQ
Structure Therapeutics Inc
$49.71
+3.03%
(+1.46) 1D
$50.01
+0.60% (+0.30)
After hours
Closed: Jun 26, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GPCR...
Open
$48.47
High
$50.29
Low
$48.19
Mkt. cap
3.53B
Avg. vol.
791.87K
Volume
885.73K
52-wk high
$94.90
52-wk low
$15.80
EPS
-$2.72
Beta
-1.43
Shares outstanding
71.07M
No. of employees
233
Open
$48.47
High
$50.29
Low
$48.19
Mkt. cap
3.53B
Avg. vol.
791.87K
Volume
885.73K
52-wk high
$94.90
52-wk low
$15.80
EPS
-$2.72
Beta
-1.43
Shares outstanding
71.07M
No. of employees
233
News stories
From sources across the web
About Structure Therapeutics Inc
CEO-
Employees233
Founded2016
HeadquartersSouth San Francisco, California, United States
SectorPharmaceutical industry
Websitestructuretx.com
Analyst ratings
Based on 8 analysts giving stock ratings to GPCR in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for GPCR in the last 3 months.
Highest
Current $49.71
$145.00 (+191.69%)
Average
$110.17 (+121.63%)
Lowest
$70.00 (+40.82%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ananda Ghosh
H.C. Wainwright
Buy
Reiterated
$70.00
+40.8%
06/11/2026
Hardik Parikh
J.P. Morgan
Buy
Maintained
-
-
06/09/2026
Prakhar Agrawal
Cantor Fitzgerald
Buy
Maintained
$101.00
+103.2%
06/07/2026
Andy Hsieh
William Blair
Buy
Reiterated
-
-
06/08/2026
Evan Seigerman
BMO Capital
Buy
Maintained
$145.00
+191.7%
06/05/2026
Patrick Dolezal
LifeSci Capital
Buy
Reiterated
$104.00
+109.2%
05/09/2026
Edward Nash
Canaccord Genuity
Buy
Reiterated
$101.00
+103.2%
05/08/2026
Seamus Fernandez
Guggenheim
Buy
Maintained
$140.00
+181.6%
05/07/2026
Corinne Johnson
Goldman Sachs
Buy
Maintained
$101.00
+103.2%
03/16/2026
Samantha Semenkow
Citi
Buy
Reiterated
$100.00
+101.2%
03/16/2026
Annabel Samimy
Stifel Nicolaus
Buy
Maintained
$90.00
+81.1%
02/27/2026
Roger Song
Jefferies
Buy
Maintained
$125.00
+151.5%
02/27/2026
Terence Flynn
Morgan Stanley
Buy
Maintained
$126.00
+153.5%
02/27/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$93.00
+87.1%
02/27/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$113.00
+127.3%
02/27/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
54.71M
58.99M
68.69M
66.51M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
15.74M
14.80M
17.57M
22.87M
Operating expense
70.45M
73.79M
-13.74M
89.38M
Total operating expenses
70.45M
73.79M
-13.74M
89.38M
Operating income
-70.45M
-73.79M
13.74M
-89.38M
Other non operating income
-
-
-13.86M
-
EBT including unusual items
-61.52M
-65.60M
33.17M
-75.78M
EBT excluding unusual items
-61.52M
-65.60M
35.75M
-75.78M
Income tax expense
139.00K
108.00K
170.00K
190.00K
Effective tax rate
-0.23%
-0.16%
0.51%
-0.25%
Other operating expenses
-
-
-100.00M
-
Net income
-61.66M
-65.71M
33.00M
-75.97M
Net profit margin
-
-
-
-
Earnings per share
-0.36
-0.37
-0.46
-0.35
Interest and investment income
8.93M
8.18M
35.87M
13.60M
Interest expense
-
-
-
-
Net interest expenses
8.93M
8.18M
35.87M
13.60M
Depreciation and amortization charges
-
-
-
-
EBITDA
-70.16M
-73.41M
14.47M
-88.79M
Gain or loss from assets sale
-
-
-10.25M
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of GPCR
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer